Prelude Therapeutics (PRLD) Other Non Operating Income (2019 - 2026)

Prelude Therapeutics has reported Other Non Operating Income for 8 years, with the latest figure at $3.8 million in Q1 2026.

• Quarterly Other Non Operating Income rose 50.42% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 million (down 47.83% YoY) and the FY2025 annual result came in at $5.1 million, down 59.59% from the prior year.
• Other Non Operating Income grew to $3.8 million in Q1 2026 per PRLD's latest filing, from $891000.0 in the prior quarter.
• Over five years, Other Non Operating Income peaked at $5.1 million in Q4 2024 and troughed at $448000.0 in Q3 2022.
• A 5-year average of $2.3 million and a median of $2.1 million in 2024 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2022 and 2025: Other Non Operating Income soared 2723.81% in 2022, then sank 82.53% in 2025.
• Over 5 years, Other Non Operating Income stood at $4.7 million in 2022, then retreated by 9.27% to $4.3 million in 2023, then grew by 18.49% to $5.1 million in 2024, then tumbled by 82.53% to $891000.0 in 2025, then soared by 325.59% to $3.8 million in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $3.8 million, $891000.0, and $693000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.